Navigation Links
Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
Date:11/10/2008

he surface of B-cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for sale in any country.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our p
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces Results for the First Nine Months of 2008
2. Genmab Reaches Milestone in Ofatumumab Collaboration
3. Genmab Reaches Fifth Milestone in Ofatumumab Collaboration
4. Genmab A/S - Changes Board/Management/Auditors
5. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
6. Genmab Announces 2008 First Quarter Results
7. Passing of Genmab A/S Annual General Meeting
8. Genmab A/S - Notice to Convene Annual General Meeting
9. Genmabs 2007 Annual Report
10. Genmab Announces Year End 2007 Financial Results
11. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)...  Bayer HealthCare (Bayer) has expanded its collaboration ... Technology (MIT) and Harvard University to include cardiovascular ... new part of the alliance is to leverage ... cardiovascular therapies. "We are excited to ... the area of cardiovascular genomics to discover genes ...
(Date:3/31/2015)... CA (PRWEB) March 31, 2015 This ... Professors from the top U.S and International Medical Schools ... their latest research on the application of stem cell ... The symposium is organized and funded by the ... nonprofit that has been convening intimate meetings of top ...
(Date:3/30/2015)... 2015 PMG Research, Benchmark Research, ... the formation of VaxCorps, a network of highly ... the conduct of vaccine trials in healthy adult, ... have successfully conducted over 500 phase I-III vaccine ... pandemic influenza as well as a vast array ...
(Date:3/30/2015)... , March 30, 2015 US-Australian drug ... and its subsidiary, CanTx, Inc., and Yale University, on ... Cantrixil. The data was presented as an oral presentation ... Yale Medical School to the 62 nd Annual ... San Francisco, CA. ...
Breaking Biology Technology:Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 2Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 3Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4
... May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( ... company specialized in oncology and endocrinology, today announced that ... product designation from the Committee for Orphan Medicinal Products ... AEZS-108 for the treatment of ovarian cancer. AEZS-108, the ...
... , May 17 Soligenix, Inc. (OTC Bulletin Board: SNGX) ... results for the first quarter of 2010. , ... Soligenix,s revenues for the first quarter of 2010 ... the first quarter of 2009. The decreased revenues were primarily a result ...
... Sigma- Aldrich announces the retirement of David Julien , President – ... on his current role in January 2009 .  He served as President ... to January 2009 and before that in a number of senior ... , , , ...
Cached Biology Technology:Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 2Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 3Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 2Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 3Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 4Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 5Sigma-Aldrich (Nasdaq: SIAL) Announces Executive Management Changes: Retirement of David Julien and Promotion of Joseph Porwoll 2
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... 2015 Beta Systems today ... access management (IAM) solution for a fixed price ... System,s new IAM package, customers benefit from the ... multiple IAM implementations across different industries. The new ... as any necessary services and consulting. It spans ...
(Date:3/11/2015)... 11, 2015   The Sync Project™ ... scientifically measure and harness music to improve health. ... and objective measurements of physiology, enabling the study ... in large populations. It is designed for medical ... perform rigorous studies and accelerate the discovery of ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... ITHACA, NY Commercial apple growers in the northeastern ... and insect invasions to tree nutrition and crop load. ... of integrated fruit production (IFP) and organic fruit production ... alternative markets. In a recent issue of HortScience ...
... Today,s most common cultivated strawberry, the familiar Fragaria x vananassa ... a chance hybridization of two wild strawberry species in Europe ... characteristics of both species, including the larger, firmer fruit of ... fruit of F. virginiana . The fact that ...
... the most important fruit trees in the world. Citrus has ... than 4,000 years. Until now, however, the exact genetic origins ... ), lemon ( C. limon ), and grapefruit ( C. ... from China has published a study in the Journal of ...
Cached Biology News:Integrated, organic production systems evaluated for 'liberty' apple 2New research expands genetic base of cultivated strawberry 2Genetic origin of cultivated citrus determined 2
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: